SecBot SecBot
Biotech Drug Report Generated Nov 3, 2026

INGREZZA

NBIX·NEUROCRINE BIOSCIENCES INC
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and marketed in the U.S. since 2017. No additional regulatory filings are pending for INGREZZA itself.
Why 4/10
INGREZZA is already approved and commercialized with no pending PDUFA date or pivotal readout for this drug. The next hard binary catalysts for Neurocrine are pipeline drugs (osavampator, direclidine) expected in 2027, not INGREZZA itself. As an approved product with steady commercial execution, INGREZZA drives revenue growth but lacks a near-term binary event.
Actionable Insight NEUTRAL

INGREZZA is a mature commercial asset with no near-term binary catalyst. Watch for Q4 2026 and full-year 2026 earnings (expected February 2027) for INGREZZA sales trajectory and 2027 guidance. The next major value inflection points for NBIX stock are likely the Phase 3 readouts for osavampator (major depressive disorder) and direclidine (schizophrenia) expected in 2027, not INGREZZA itself.

Price Chart

Loading chart...

Executive Summary

INGREZZA (valbenazine) is Neurocrine Biosciences' flagship product, a VMAT2 inhibitor approved for tardive dyskinesia (2017) and chorea associated with Huntington's disease (2023). It generated $801 million in Q3 2026 sales (up 17% YoY), with full-year guidance raised to $2.9-$2.925 billion. The drug faces competition from Teva's Austedo (deutetrabenazine) but has demonstrated superior VMAT2 target occupancy in head-to-head data. A Phase 3 trial in dyskinetic cerebral palsy failed in 2026, and key patents face generic challenges with settlements allowing entry around 2038. The stock trades at ~$145 with a strong analyst consensus (32 analysts: 15 strong buy, 17 buy, 5 hold) and a mean price target of ~$206 (42% implied upside).

How It Works

INGREZZA is a VMAT2 inhibitor. It works by blocking a protein called vesicular monoamine transporter 2 (VMAT2), which reduces the release of dopamine in certain areas of the brain. This helps control involuntary movements seen in tardive dyskinesia and chorea associated with Huntington's disease.

Trial Status

INGREZZA was first FDA-approved in April 2017 for tardive dyskinesia and received a label expansion in August 2023 for chorea associated with Huntington's disease. The INGREZZA SPRINKLE formulation was approved in April 2024. A Phase 3 trial (KINECT-DCP) in dyskinetic cerebral palsy failed to meet its primary and key secondary endpoints in 2026. A Phase 4 open-label study (KINECT-PRO) published in August 2026 showed improvements in patient-reported quality of life and daily functioning in tardive dyskinesia.

The Two-Sided Case

▲ Bull Case5
INGREZZA continues to deliver strong commercial growth: Q3 2026 sales of $801 million were up 17% year-over-year, and full-year 2026 guidance was raised to $2.9-$2.925 billion.
Head-to-head PET imaging data showed INGREZZA achieves nearly two-fold higher VMAT2 target occupancy versus Austedo XR, supporting a differentiated efficacy narrative.
Neurocrine expects double-digit volume growth for INGREZZA in 2027, which management believes will more than offset mid-to-high single-digit net pricing headwinds.
Analyst consensus is strongly bullish: 32 analysts rate the stock with a mean price target of ~$206 (42% implied upside from ~$145), with 15 strong buy and 17 buy ratings.
The company now has three commercial products (INGREZZA, CRENESSITY, VYKAT XR), diversifying beyond INGREZZA alone.
▼ Bear Case5
INGREZZA faces patent cliff risk: key patents are challenged by generics, with settlements allowing generic valbenazine entry as early as March 2038, and some patent expirations as early as 2027-2028.
A Phase 3 trial (KINECT-DCP) in dyskinetic cerebral palsy failed to meet primary and key secondary endpoints in 2026, closing off a potential label expansion opportunity.
The drug faces mid-to-high single-digit net pricing headwinds expected in 2027, which could pressure revenue growth.
Several large institutional holders trimmed or exited positions in Q2 2026, including Wellington Management (near-exit, -97.5%), Millennium Management (near-exit, -99.1%), and UBS (trim, -55.3%).
Competition from Teva's Austedo/Austedo XR and generic tetrabenazine limits pricing power and market share.

Upcoming Catalysts

  • No hard binary catalyst for INGREZZA specifically (already approved). Neurocrine's next major pipeline catalysts are osavampator Phase 3 data in major depressive disorder and direclidine Phase 3 data in schizophrenia, expected in 2027.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

NEUROCRINE BIOSCIENCES INC 8-K NBIX ·Originating report

Sources · 9

Hover a chip for the title
1 prnewswire.com2 prnewswire.com3 prnewswire.com4 prnewswire.com5 prnewswire.com6 biospace.com7 stocktitan.net8 drugpatentwatch.com9 accessdata.fda.gov